BD DIAGNOSTICS

Franklin Lakes, New Jersey, U.S. All United States companies → — Founded 1897

Healthcare Conglomerate Medical Device / Hardware Point-of-Care Diagnostics

Obstetrics & Gynecology Pathology

OB/GYN AI Oncology AI Pathology AI

Publicly Traded (NYSE: BDX) — Publicly traded company

Claim this company

Products

AUTOPAP(R) 300 QC AUTOMATIC PAP SCREENER/QC SYSTEM

BD DIAGNOSTICS

OB/GYN AI

The AutoPap 300 QC System is an automated device for the analysis of conventionally prepared cervical cytology slides, designed to enhance quality control by identifying cases for further human review and reducing false negatives in Pap smear screening.

Not publicly available

See all 1 product →

About BD DIAGNOSTICS

Becton, Dickinson and Company (BD) is a global medical technology company dedicated to advancing the world of health by improving medical discovery, diagnostics, and the delivery of care. While the term “BD Diagnostics” historically referred to a significant segment of the company focused on diagnostic solutions, this business unit, specifically “Biosciences & Diagnostic Solutions,” was recently spun off and merged with Waters Corporation in February 2026. Prior to this, BD Diagnostics played a crucial role in providing innovative solutions for infectious diseases, cancer screening, and microbiology, including the integration of artificial intelligence to enhance diagnostic accuracy and efficiency.

Currently, BD (the parent company) continues to be a prominent player in healthcare AI, particularly within its Connected Care and Medication Management Solutions segments. For physicians, BD offers AI-powered solutions designed to optimize clinical operations and improve patient outcomes. Examples include AI software highly effective in detecting indicators of controlled substance diversion within hospital settings, enhancing patient safety and compliance. Furthermore, BD has launched the BD Incada™ Connected Care Platform, a scalable, AI-enabled, cloud-based platform that unifies data from millions of smart BD medical devices to provide enterprise-wide visibility into medication inventory, reduce waste, and improve labor efficiency through natural language search and actionable insights.

BD’s commitment to AI extends to research and development, with tools like BD® Research Cloud 7.0 featuring BD Horizon™ Panel Maker, an AI-powered tool for automated panel design in immunology and cancer research, aimed at improving the quality and efficiency of scientific results. Although the traditional diagnostics business is now part of the Waters-BD Biosciences & Diagnostic Solutions combined entity, BD maintains a strong focus on leveraging AI and advanced analytics across its remaining portfolio to transform care delivery, from smart medical devices and lab automation to connected medication management and advanced patient monitoring.

Focus Areas

Medical discovery diagnostics delivery of care patient safety medication management infection prevention surgical procedures diabetes management immunology cancer research flow cytometry microbiology molecular diagnostics lab automation informatics controlled substance diversion hemodynamic monitoring cervical cytology antimicrobial resistance

Business Intelligence

Key Investors	N/A
Partnerships	Techcyte (AI-based digital cervical cytology), Microsoft (HealthSight Diversion Management algorithms), Ypsomed (prefillable syringe production)
Acquisitions	C. R. Bard (2017), CareFusion (2015), Tepha (2021), Velano Vascular (2021), Edwards Lifesciences' critical care unit (2024 acquisition announced)
Technology	BD HealthSight™ Diversion Management software (AI, machine learning, advanced analytics), BD® Research Cloud 7.0 with BD Horizon™ Panel Maker (AI-powered automated panel design for flow cytometry), BD Incada™ Connected Care Platform (AI-enabled, cloud-based on AWS, natural language search, unifies device data), HemoSphere Alta™ Advanced Monitoring Platform (predictive, AI-based algorithms, Hypotension Prediction Index (HPI), Cerebral Autoregulation Index (CAI)), BD Kiestra™ MRSA imaging application (AI for microbiology lab automation), BD Phoenix M50 and BDXpert System on BD Synapsys Informatics Solution (AI/algorithms for ID/AST in microbiology)
FDA Clearances	Multiple, including several AI-powered solutions (e.g., BD Kiestra™ MRSA imaging application, HemoSphere Alta™'s HPI algorithm, BD Phoenix M50 and BDXpert System) cleared products (estimated)

What Physicians Need to Know

Medical Discovery, Immunology, Cancer Research & Flow Cytometry

BD is a leader in immunology and cancer research, offering solutions including flow cytometry instruments and reagents, and innovative single-cell multiomics tools. Their BD CellViewu2122 Image Technology integrates fluorescence imaging and image-based decision-making to sort individual cells at high speed (15,000 cells per second) based on visual details, not solely biomarkers. This advancement allows for deep immune profiling and the identification and analysis of rare cell types, transforming immunology, cell biology, and genomics research. Key differentiators include overcoming the speed-precision compromise in cell sorting and analyzing over 1,000 times more data than traditional methods. Their FACSymphonyu2122 family offers high-parameter spectral flow cytometry, enabling full visible spectrum coverage, increased dye flexibility, and autofluorescence unmixing.

Diagnostics, Microbiology, Molecular Diagnostics & Lab Automation

BD provides comprehensive microbiology solutions for rapid, high-quality pathogen identification and antimicrobial susceptibility testing (ID/AST). They offer fully automated, high-throughput molecular diagnostics platforms like the BD CORu2122 System for infectious diseases, including STIs and HPV, which integrates robotics and sample management software. BD Kiestrau2122 solutions deliver standardized and scalable lab automation for inoculation, incubation, plate imaging, culture reading, and reporting, significantly improving efficiency and turnaround time. The BD Synapsysu2122 microbiology informatics solution ensures secure connectivity across instruments and locations, streamlining workflows, automating manual processes, and providing on-demand actionable insights to boost productivity and compliance. BD is at the forefront of combating antimicrobial resistance (AMR) through enhanced diagnostic solutions, surveillance, and reporting capabilities.

Delivery of Care, Patient Safety & Medication Management

BD offers Connected Medication Management, a technology-driven approach to automate, streamline, and digitalize all steps from prescription to administration, enhancing inventory management, medication traceability, and safety. Solutions such as the BD Pyxisu2122 ES platform and the AI-enabled BD Pyxisu2122 Pro Dispensing Solution provide enterprise-wide medication management, secure controlled substance management, and advanced security features. BD delivers advanced IV medication safety solutions, including Alarisu2122 Plus Pumps with Guardrailsu2122 Safety Software and the Alarisu2122 Communication Engine Platform for automated centralized management of connected infusion devices. They also provide advanced hemodynamic monitoring solutions like the VitaWaveu2122 Plus System for continuous noninvasive blood pressure insight, aiding in earlier detection and treatment of intraoperative hypotension. BD is deeply committed to patient and healthcare worker safety, offering products and services to prevent patient safety events and healthcare-associated infections (HAIs).

Surgical Procedures

BD contributes to surgical procedures primarily through infection prevention products, including sterilization accessories, antimicrobial devices, and surgical prep solutions. Their focus is on reducing surgical wound contamination and preventing infections, which are critical for positive patient outcomes.

Diabetes Management

BD offers essential diabetes management tools such as insulin syringes, pen needles, and lancets, alongside educational devices for accurate and comfortable self-management. They have developed the BDu2122 Diabetes Care App, a digital hub for managing Type 2 diabetes, providing personalized coaching, tracking personal health data, and offering educational and emotional support. The app leverages AI conversations to identify behavioral trends, offering adaptive learning and expert content to empower patients and facilitate more meaningful discussions with healthcare providers.

Cervical Cytology

BD provides advanced molecular and cytology testing solutions for cervical cancer screening, including the BD SurePathu2122 Liquid-based Pap Test. They have a strategic collaboration to offer an AI-based digital cervical cytology system that guides cytologists and pathologists in efficiently identifying cervical cancer and precancer using whole-slide imaging. This system utilizes an AI-based algorithm to prioritize clinically relevant cells, aiming to reduce human error, increase throughput, and ensure standardization and reproducibility in Pap tests, thereby addressing the shortage of healthcare laboratory technicians. The BD FocalPointu2122 GS Imaging System further enhances detection and screening efficiency by prioritizing slide review and increasing HSIL+ and cancer detection rates.

Physician Tip

For physicians, BD DIAGNOSTICS stands out by offering integrated, automated, and AI-enhanced solutions that aim to improve diagnostic accuracy, streamline workflows, and enhance patient safety across multiple care settings. Their focus on rapid and precise diagnostics, particularly in microbiology and molecular testing, can lead to quicker, more informed treatment decisions, especially in critical areas like antimicrobial resistance and sepsis management. The advanced informatics solutions provide actionable insights, reducing manual errors and improving turnaround times. In patient care, their connected medication management systems help minimize medication errors and ensure efficient drug delivery. Furthermore, innovations in flow cytometry and cervical cytology offer powerful tools for research and early disease detection, ultimately supporting better patient outcomes and operational efficiency in the clinic and laboratory.

BD DIAGNOSTICS emphasizes integrated solutions across its portfolio. Their systems, such as BD Synapsysu2122 and BD CORu2122, are designed for secure connectivity across instruments and locations, facilitating seamless data flow between laboratory instruments, informatics platforms, and potentially hospital information systems (HIS) or electronic medical records (EMR). This integration aims to streamline workflows, automate manual processes, and provide a holistic view of patient data, which is crucial for comprehensive care and operational efficiency.

At a glance

Founded 1897

HQ Franklin Lakes, New Jersey, U.S. · United States

Team size Approximately 70,000 (as of 2025)

CEO Tom Polen

Funding Publicly Traded (NYSE: BDX) — Publicly traded company

FDA clearances Multiple, including several AI-powered solutions (e.g., BD Kiestra™ MRSA imaging application, HemoSphere Alta™'s HPI algorithm, BD Phoenix M50 and BDXpert System) (estimated)

Products 1

Products by BD DIAGNOSTICS

1 product in the directory

AUTOPAP(R) 300 QC AUTOMATIC PAP SCREENER/QC SYSTEM

BD DIAGNOSTICS

OB/GYN AI

Not publicly available

What the Web Says

BD Diagnostics, a division of BD (Becton, Dickinson and Company), is a global medical technology company that develops and sells medical devices, laboratory equipment, and diagnostic products. The company aims to improve diagnostics, enhance care, and transform lives globally. Reviews for BD Diagnostics cover both its products and its employer practices, with a mixed sentiment across various platforms.

Overall: Mixed

Strengths

Good opportunities and support for career advancement within the company.
Competitive pay and benefits.
Supportive work environment and opportunities for personal and professional development.
Some employees report a positive work culture and feeling valued.
Products like the BD MAXu2122 system and BD BACTECu2122 FX Blood Culture System are highlighted for efficiency and advanced technology.
BD Biosciences website is praised for ease of use and efficiency for placing orders.

Limitations

Management can be ineffective, with issues of favoritism and poor communication reported in some locations.
Some products, like the BD Viper analyzer, have received extremely negative reviews due to frequent breakdowns and high costs.
The company culture can be perceived as large and corporate, with potential for conflicts between corporate and regional teams.
Difficulty in finding the correct stakeholders due to a top-heavy supply chain organization.
Concerns about work-life balance and job security in certain roles and locations.
Some former employees have expressed that the company's practices can disregard integrity and customer interests.

Based on reviews from: Indeed.com, Reddit, SelectScience, BD.com, G2, Capterra

Last updated: 2026-07-17

Videos

News, demos, and interviews about BD DIAGNOSTICS.

Loading videos...

Videos load interactively. If none appear, search YouTube for BD DIAGNOSTICS →

View all on YouTube

Press & Coverage

Select Science

BD Unveils Latest Diagnostic Innovations at ECCMID

BD introduced new informatics and automation solutions for clinical laboratories at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), including the BD Synapsysu2122 microbiology informatics solution. These innovations aim to streamline workflows, automate manual processes, and provide actionable insights to improve productivity and compliance in the fight against infectious diseases and antimicrobial resistance.

2026-05

MLO Online

What BD Selling Its Diagnostics Business Could Mean for Clinical Labs

Becton Dickinson's (BD) announcement to sell or spin off its in vitro diagnostics (IVD) and life science businesses by 2026 will significantly impact the IVD market, potentially leading to consolidation and new vendor relationships for clinical labs. The company intends to focus more on the medical technology market, with its IVD and life sciences division generating $3.4 billion in revenue in fiscal year 2024.

2025-02

The Boston Globe

Milford's Waters Corp. strikes $17.5 billion deal to merge with BD's diagnostics unit

Waters Corp. of Milford will acquire BD's biosciences and diagnostic solutions unit in a stock-and-cash deal valued at $17.5 billion, with the transaction expected to close by the end of the first quarter of 2026. BD will spin off the diagnostics unit, which will then merge with a wholly-owned Waters subsidiary, with BD shareholders receiving 39.2 percent of the combined company and $4 billion in cash.

2025-07

Default Credentials u2013 BD Diagnostic Solutions Products

BD issued a cybersecurity notification regarding a default credential vulnerability in specific BD Diagnostic Solutions products, including the BD BACTECu2122 Blood Culture System and BD MAXu2122 System. Remediation solutions are being deployed, and BD representatives will proactively contact impacted customers to schedule the necessary updates.

2025-01

MDPI

Multicenter Analytical Performance Evaluation of the BD Phoenix NMIC-461 Panel for Carbapenemase Classification and Antimicrobial Susceptibility Testing of Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter spp.

A multicenter study evaluated the BD Phoenix NMIC-461 panel for carbapenemase classification and antimicrobial susceptibility testing, demonstrating robust performance for Enterobacterales and Acinetobacter spp., with overall sensitivity and specificity above 92% for CPO detection. The study highlighted the panel's strong concordance for imipenem AST, though performance was less robust for P. aeruginosa isolates.

2026-03

Fierce Biotech

BD joins Day Zero's $21M fundraising for sequencing-based infectious disease diagnostics

BD participated in Day Zero Diagnostics' $21 million funding round, supporting the development of sequencing-based infectious disease diagnostics to combat antibiotic-resistant infections. Brooke Story, President of Integrated Diagnostic Solutions at BD, will join Day Zero's board as an observer, signaling BD's belief in the future role of genome sequencing in infectious disease diagnostics.

2022-02

BD Newsroom

BD Announces Streamlined Reporting Capabilities for COVID-19 Data

BD announced new streamlined reporting capabilities for COVID-19 data through its BD Synapsysu2122 Informatics solution, enabling global customers to generate general-purpose and configured reports from BD Veritoru2122 and BD MAXu2122 systems. This enhancement aims to reduce the burden of manual reporting and allow healthcare providers to focus on patient care.

2020-11

ASM Journals

Evaluation of the BD Max Enteric Parasite Panel for Clinical Diagnostics

A study evaluated the BD Max enteric parasite panel for detecting Giardia intestinalis, Entamoeba histolytica, and Cryptosporidium spp., showing good specificity for all targets and good sensitivity for E. histolytica and Cryptosporidium spp. The panel, which uses integrated DNA extraction and PCR, demonstrated equivalent sensitivity to microscopy for G. intestinalis.

2015

Frequently Asked Questions

What is the current scope of BD Diagnostics' offerings for healthcare providers, encompassing diagnostics, patient safety, and infection prevention?

BD Diagnostics provides a broad range of solutions aimed at advancing medical discovery, enhancing the diagnosis of infectious diseases and cancer, and improving patient care. This includes comprehensive microbiology and molecular diagnostics, patient safety solutions, and products designed to promote infection prevention. The company's portfolio supports various clinical needs from laboratory testing to the delivery of care.

How is BD Diagnostics addressing the growing concern of antimicrobial resistance (AMR) and enhancing diagnostic accuracy in microbiology?

BD Diagnostics offers advanced solutions to combat antimicrobial resistance, including assays for healthcare-associated infections like the BD MAXu2122 MRSA assay for rapid and accurate diagnosis. Their microbiology solutions and informatics platforms, such as BD Synapsysu2122, aim to improve diagnostic accuracy and efficiency, providing critical data for effective treatment strategies. These tools help laboratories maximize performance and address challenges in infectious disease management.

What are BD Diagnostics' key innovations and partnerships in areas like flow cytometry, immunology, cancer research, and laboratory automation?

BD Diagnostics is a leader in flow cytometry innovation, which is being leveraged in partnerships with Quest Diagnostics and Labcorp to develop companion diagnostics for cancer and other diseases, advancing personalized medicine. Additionally, BD has collaborated with Biosero to integrate robotic automation with flow cytometers, accelerating drug discovery and development workflows. These collaborations aim to provide end-to-end solutions for pharmaceutical partners and enhance research capabilities.

How does BD Diagnostics ensure regulatory compliance and product quality for its diagnostic solutions?

BD Diagnostics maintains robust quality management systems that comply with global regulations and industry standards, including ISO 13485:2016 and FDA Quality System Regulations (QSRs). The company is also actively working towards compliance with the European In Vitro Diagnostic Medical Device Regulation (IVDR) for its relevant product portfolio. This commitment ensures the predictable delivery of high-quality and effective products for patient and customer safety.

What impact will the announced separation of BD's Biosciences and Diagnostic Solutions business have on healthcare providers and their access to BD Diagnostics' products and support?

BD announced a plan to separate its Biosciences and Diagnostic Solutions business, expected to be completed by the end of 2026, to create a focused leader in life sciences tools and diagnostics. While the 'New BD' will concentrate on medical technology, the divested entity will continue to offer the diagnostic and biosciences portfolio. BD has stated that there will be no immediate changes in how customers order products, process payments, or contact sales and support during this transition.

Does BD Diagnostics offer solutions for medication management, patient safety, and informatics to optimize care delivery?

Yes, BD provides comprehensive solutions for medication management and patient safety, which are critical for optimizing care delivery. While the specific 'BD Diagnostics' segment focuses on testing, the broader BD company offers medication management solutions, patient safety solutions, and informatics tools like the BD Synapsysu2122 solution to enhance laboratory outcomes and integrate diagnostic pathways. These offerings contribute to improving efficiencies and safety across healthcare settings.

Related Companies

Suggest an Edit →